AR110543A1 - [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas - Google Patents
[4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonasInfo
- Publication number
- AR110543A1 AR110543A1 ARP170103563A ARP170103563A AR110543A1 AR 110543 A1 AR110543 A1 AR 110543A1 AR P170103563 A ARP170103563 A AR P170103563A AR P170103563 A ARP170103563 A AR P170103563A AR 110543 A1 AR110543 A1 AR 110543A1
- Authority
- AR
- Argentina
- Prior art keywords
- haloalkoxy
- nitro
- alkoxy
- group
- haloalkyl
- Prior art date
Links
- -1 PHENYL SULFONYL Chemical class 0.000 title abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 title 1
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 7
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- RKDCAZBUEMNOLS-UHFFFAOYSA-N [4-(benzenesulfonyl)piperazin-1-yl]-(2H-triazol-4-yl)methanone Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C=1N=NNC=1 RKDCAZBUEMNOLS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente cubre compuestos de [4-(fenilsulfonil)piperazin-1-il](1H-1,2,3-triazol-4-il)metanona, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de composiciones farmacéuticas para el tratamiento o profilaxis de trastornos, en particular de trastornos ginecológicos, trastornos hiperproliferativos, trastornos metabólicos o trastornos inflamatorios como un agente único o en combinación con otros ingredientes activos. Reivindicación 1: Un compuesto de fórmula general (1), en la cual R¹ representa hidrógeno, halógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro o ciano; R² representa hidrógeno, halógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro, ciano o SF₅; R³ representa hidrógeno, halógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro o hidroxi; o R¹ y R² o R² y R³ forman en forma conjunta un metilendioxi, etilendioxi, etilenoxi, trimetilenoxi o un grupo seleccionado entre el grupo de fórmulas (2); R⁴ representa hidrógeno, halógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro, ciano o SF₅; R⁵ representa hidrógeno, halógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro o ciano, caracterizado porque cuando R³ representa halógeno y R¹, R² y R⁴ representan hidrógeno, entonces R⁵ representa hidrógeno, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro o ciano, o cuando R³ representa alquilo C₁₋₃ o haloalquilo C₁₋₃ y R¹, R² y R⁴ representan hidrógeno, entonces R⁵ representa, alcoxi C₁₋₃, haloalcoxi C₁₋₃, nitro o ciano; Q representa un grupo seleccionado entre el grupo de fórmulas (3), donde * indica el punto de unión de dicho grupo al grupo carbonilo y ** indica el punto de unión de dicho grupo al grupo sulfonilo de la molécula; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato, o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16205077 | 2016-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110543A1 true AR110543A1 (es) | 2019-04-10 |
Family
ID=57570711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103563A AR110543A1 (es) | 2016-12-19 | 2017-12-19 | [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200079758A1 (es) |
| EP (1) | EP3555075A1 (es) |
| AR (1) | AR110543A1 (es) |
| CA (1) | CA3047188A1 (es) |
| TW (1) | TW201825478A (es) |
| UY (1) | UY37530A (es) |
| WO (1) | WO2018114670A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202215661D0 (en) * | 2022-10-21 | 2022-12-07 | Univ Birmingham | PCOS stratification |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL343862A1 (en) | 1998-03-11 | 2001-09-10 | Endorech | Inhibitors of type 5 and type 3 17β−hydroxysteroid dehydrogenase and methods for their use |
| AU6715200A (en) | 1999-09-04 | 2001-04-10 | Astrazeneca Ab | Amides as inhibitors for pyruvate dehydrogenase |
| WO2007103456A2 (en) | 2006-03-06 | 2007-09-13 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
| WO2007111921A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| WO2008024284A2 (en) | 2006-08-21 | 2008-02-28 | Merck & Co., Inc. | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2013059245A1 (en) | 2011-10-17 | 2013-04-25 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| WO2013142390A1 (en) | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
| BR112015000443A2 (pt) | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos |
| WO2014039820A1 (en) | 2012-09-07 | 2014-03-13 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
| AP3826A (en) | 2013-02-21 | 2016-09-30 | Bayer Pharma Aktiengellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3) |
| US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
-
2017
- 2017-11-29 TW TW106141526A patent/TW201825478A/zh unknown
- 2017-12-15 EP EP17822248.5A patent/EP3555075A1/en not_active Withdrawn
- 2017-12-15 US US16/469,861 patent/US20200079758A1/en not_active Abandoned
- 2017-12-15 CA CA3047188A patent/CA3047188A1/en not_active Abandoned
- 2017-12-15 WO PCT/EP2017/083031 patent/WO2018114670A1/en active Application Filing
- 2017-12-19 AR ARP170103563A patent/AR110543A1/es unknown
- 2017-12-19 UY UY0001037530A patent/UY37530A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018114670A1 (en) | 2018-06-28 |
| TW201825478A (zh) | 2018-07-16 |
| US20200079758A1 (en) | 2020-03-12 |
| CA3047188A1 (en) | 2018-06-28 |
| UY37530A (es) | 2018-07-31 |
| EP3555075A1 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102948A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 | |
| AR091093A1 (es) | Tienopirimidinas | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR095011A1 (es) | Compuestos de antranilamida, sus mezclas y usos como plaguicidas | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR092607A1 (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY31612A1 (es) | Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| AR097435A1 (es) | 6-alquinilpiridinas | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR095059A1 (es) | Compuestos herbicidas | |
| AR097138A1 (es) | Compuestos plaguicidas | |
| UY37262A (es) | [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas | |
| AR093801A1 (es) | Derivados de 1,4-ditiina sustituida y su uso como fungicidas | |
| AR090323A1 (es) | Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1 | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |